iopharma has suffered some scares this year in Washington, D.C., and on Wall Street, but from a science perspective, the industry has performed admirably, particularly with big advances in cancer immunotherapy and gene therapy.

I pored over spreadsheets, dug deep into medical journals, stared at stock charts, and consulted my beloved dog, Bo, to determine this year’s nominees for best biopharma CEO. There were some hard decisions to make and a few worthy candidates didn’t make the cut, mainly because the bar this year was so high. Congratulations to each of the finalists.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.